NASDAQ:ONCS OncoSec Medical Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding OncoSec Medical Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. $0.74 -0.07 (-8.62%) (As of 06/30/2022 12:00 AM ET) Add Compare Share Today's Range$0.74▼$0.8650-Day Range$0.70▼$0.9052-Week Range$0.67▼$4.25Volume34,677 shsAverage Volume92,892 shsMarket Capitalization$29.21 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ONCS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OncoSec Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address ONCS Stock Forecast (MarketRank)Overall MarketRank™1.76 out of 5 starsMedical Sector842nd out of 1,433 stocksPharmaceutical Preparations Industry415th out of 684 stocksAnalyst Opinion: 3.5Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingOncoSec Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, OncoSec Medical has a forecasted upside of 573.9% from its current price of $0.74.Amount of Analyst CoverageOncoSec Medical has received no research coverage in the past 90 days. Previous Next 3.9 Community Rank Outperform VotesOncoSec Medical has received 313 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOncoSec Medical has received 222 “underperform” votes. (Add your “underperform” vote.)Community SentimentOncoSec Medical has received 58.50% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about OncoSec Medical and other stocks. Vote “Outperform” if you believe ONCS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ONCS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOncoSec Medical does not currently pay a dividend.Dividend GrowthOncoSec Medical does not have a long track record of dividend growth. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OncoSec Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $227.00 in company stock.Percentage Held by InsidersOnly 2.73% of the stock of OncoSec Medical is held by insiders.Percentage Held by InstitutionsOnly 13.98% of the stock of OncoSec Medical is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for OncoSec Medical are expected to decrease in the coming year, from ($0.59) to ($0.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OncoSec Medical is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OncoSec Medical is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOncoSec Medical has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About OncoSec Medical (NASDAQ:ONCS)OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in clinical trials collaboration and supply agreement (KEYNOTE-695) and metastatic triple negative breast cancer, which is in Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, the company is developing monotherapy biomarker study in patients with advanced or metastatic TNBC that has completed the Phase II clinical trials; and technology to treat liver, lung, bladder, pancreatic, and other visceral lesions. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine; a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and enhanced IL-12 DNA-plasmid; and collaboration with Providence Cancer Institute. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. The company was incorporated in 2008 and is headquartered in Pennington, New Jersey.Read More ONCS Stock News HeadlinesJuly 1, 2022 | americanbankingnews.comOncoSec Medical (NASDAQ:ONCS) Now Covered by Analysts at StockNews.comJune 30, 2022 | americanbankingnews.comCritical Analysis: OncoSec Medical (NASDAQ:ONCS) vs. Atossa Therapeutics (NASDAQ:ATOS)June 23, 2022 | americanbankingnews.comOncoSec Medical (NASDAQ:ONCS) Receives New Coverage from Analysts at StockNews.comJune 16, 2022 | americanbankingnews.comOncoSec Medical (NASDAQ:ONCS) Posts Earnings Results, Beats Estimates By $0.02 EPSApril 29, 2022 | seekingalpha.comRobert Arch joins OncoSec Medical as CEOApril 29, 2022 | finance.yahoo.comOncoSec Appoints Dr. Robert Arch as President and Chief Executive OfficerMarch 16, 2022 | benzinga.comBTIG Maintains Buy on OncoSec Medical, Lowers Price Target to $5February 23, 2022 | seekingalpha.comOncoSec appoints new finance chiefOctober 9, 2021 | nasdaq.comOncoSec Medical Inc Shares Approach 52-Week Low - Market MoverAugust 3, 2021 | finance.yahoo.comOncoSec to Participate in Fireside Chat at BTIG Virtual Biotechnology ConferenceJuly 27, 2021 | nasdaq.comOncoSec Medical Incorporated Common Stock (ONCS)July 7, 2021 | marketwatch.comOncoSec Hikes on Start of Clinical TrialJuly 7, 2021 | benzinga.comWhy Shares Of OncoSec Medical Are Trading Higher TodaySee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ONCS CUSIPN/A CIK1444307 Webwww.oncosec.com Phone(858) 662-6732Fax858-430-3832Employees54Year FoundedN/ACompany Calendar Last Earnings6/14/2022Today6/30/2022Fiscal Year End7/31/2022Next Earnings (Estimated)11/04/2022Price Target and Rating Average Stock Price Forecast$5.00 High Stock Price Forecast$5.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+573.9%Consensus RatingBuy Rating Score (0-4)3 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-45.17 million Net MarginsN/A Pretax MarginN/A Return on Equity-150.20% Return on Assets-91.55% Debt Debt-to-Equity RatioN/A Current Ratio4.51 Quick Ratio4.51 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.97 per share Price / Book0.76Miscellaneous Outstanding Shares39,366,000Free Float38,291,000Market Cap$29.21 million OptionableNot Optionable Beta2.03 OncoSec Medical Frequently Asked Questions Should I buy or sell OncoSec Medical stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoSec Medical in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" OncoSec Medical stock. View analyst ratings for OncoSec Medical or view top-rated stocks. What is OncoSec Medical's stock price forecast for 2022? 1 brokers have issued 1-year target prices for OncoSec Medical's stock. Their ONCS stock forecasts range from $5.00 to $5.00. On average, they expect OncoSec Medical's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 573.9% from the stock's current price. View analysts' price targets for OncoSec Medical or view top-rated stocks among Wall Street analysts. How has OncoSec Medical's stock price performed in 2022? OncoSec Medical's stock was trading at $0.9596 on January 1st, 2022. Since then, ONCS stock has decreased by 22.7% and is now trading at $0.7419. View the best growth stocks for 2022 here. When is OncoSec Medical's next earnings date? OncoSec Medical is scheduled to release its next quarterly earnings announcement on Friday, November 4th 2022. View our earnings forecast for OncoSec Medical. How were OncoSec Medical's earnings last quarter? OncoSec Medical Incorporated (NASDAQ:ONCS) announced its quarterly earnings data on Tuesday, June, 14th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.18) by $0.02. View OncoSec Medical's earnings history. When did OncoSec Medical's stock split? How did OncoSec Medical's stock split work? OncoSec Medical shares reverse split on the morning of Tuesday, May 21st 2019. The 1-10 reverse split was announced on Monday, May 20th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 20th 2019. An investor that had 100 shares of OncoSec Medical stock prior to the reverse split would have 10 shares after the split. Who are OncoSec Medical's key executives? OncoSec Medical's management team includes the following people: Mr. Robert J. DelAversano CPA, VP of Fin. and Principal Accounting Officer & Controller (Age 50, Pay $361.18k) (LinkedIn Profile)Dr. Robert H. Arch Ph.D., Pres & CEOMr. George Chi C.F.A., CPA, Chief Financial Officer (Age 52)Dr. Kim Jaffe, Assistant VP of Bus. Devel. & OperationsMr. Tu Diep M.Sc., Sr. VP & Head of OperationsDr. Sandra Aung Ph.D., Sr. VP & Chief Clinical Devel. OfficerDr. Mai Hope Le M.D., Consultant (Age 46) What is Punit Dhillon's approval rating as OncoSec Medical's CEO? 2 employees have rated OncoSec Medical CEO Punit Dhillon on Glassdoor.com. Punit Dhillon has an approval rating of 50% among OncoSec Medical's employees. This puts Punit Dhillon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of OncoSec Medical's key competitors? Some companies that are related to OncoSec Medical include Nabriva Therapeutics (NBRV), Actinium Pharmaceuticals (ATNM), Actinium Pharmaceuticals (ATNM), RVL Pharmaceuticals (RVLP), Evelo Biosciences (EVLO), Werewolf Therapeutics (HOWL), Homology Medicines (FIXX), Applied Molecular Transport (AMTI), Gelesis (GLS), Vascular Biogenics (VBLT), Praxis Precision Medicines (PRAX), Greenwich LifeSciences (GLSI), Endo International (ENDP), DURECT (DRRX) and Trevi Therapeutics (TRVI). View all of ONCS's competitors. What other stocks do shareholders of OncoSec Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other OncoSec Medical investors own include Cytokinetics (CYTK), Inovio Pharmaceuticals (INO), XOMA (XOMA), Anavex Life Sciences (AVXL), Walt Disney (DIS), Idera Pharmaceuticals (IDRA), Sorrento Therapeutics (SRNE), Amarin (AMRN), Dynavax Technologies (DVAX) and Trevena (TRVN). What is OncoSec Medical's stock symbol? OncoSec Medical trades on the NASDAQ under the ticker symbol "ONCS." How do I buy shares of OncoSec Medical? Shares of ONCS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is OncoSec Medical's stock price today? One share of ONCS stock can currently be purchased for approximately $0.74. How much money does OncoSec Medical make? OncoSec Medical (NASDAQ:ONCS) has a market capitalization of $29.21 million. The biotechnology company earns $-45.17 million in net income (profit) each year or ($0.95) on an earnings per share basis. How many employees does OncoSec Medical have? OncoSec Medical employs 54 workers across the globe. How can I contact OncoSec Medical? OncoSec Medical's mailing address is 3565 GENERAL ATOMICS COURT, SAN DIEGO CA, 92121. The official website for OncoSec Medical is www.oncosec.com. The biotechnology company can be reached via phone at (858) 662-6732, via email at [email protected], or via fax at 858-430-3832. This page (NASDAQ:ONCS) was last updated on 7/1/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
